GlassScriptPhysician profile
Mohammad Modar Alsolaiman
NPI 1215986484
$11,053.19
in general payments reported to CMS, 2019-2025
42 companies · $1,421 in 2025
The $1,421 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,153 · 2020: $885 · 2021: $2,532 · 2022: $1,396 · 2023: $1,685 · 2024: $1,981 · 2025: $1,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,001 · Education: $85.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,001.49 |
| Education | $85.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,547.39 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Boston Scientific Corporation | $1,499.17 | 2019-2025 | General - Biliary Devices |
| Takeda Pharmaceuticals U.S.A., INC. | $1,066.57 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $821.68 | 2019-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $497.51 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Gilead Sciences, INC. | $358.52 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $346.70 | 2019-2025 | Ocaliva |
| Genzyme Corporation | $325.42 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $314.56 | 2022-2025 | Dupixent |
| Pfizer INC. | $299.34 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $272.85 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $159.28 | 2019-2023 | Dificid |
| Organon LLC | $137.41 | 2021-2025 | Hadlima, Renflexis |
| E.R. Squibb & Sons, L.L.C. | $130.24 | 2021 | |
| Aimmune Therapeutics, INC. | $126.32 | 2024-2025 | Vowst, Zenpep |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Alsolaiman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.